Leukemia News and Research

RSS

Leukemia (Leukaemia) is a cancer of the blood cells. It is the most common type of blood cancer and affects 10 times as many adults as children. Most people diagnosed with leukemia are over 50 years old. No one knows why some people develop leukemia and others do not. However, scientists have identified some risk factors for the disease. Most people who have known risk factors do not get leukemia, while many who do get the disease have none of these risk factors. During the early stages of leukemia, there may be no symptoms. Many of the symptoms of leukemia don't become apparent until a large number of normal blood cells are crowded out by leukemia cells.

EntreMed regains compliance with NASDAQ $1.00 minimum closing bid price requirement

EntreMed, Inc., today announced receipt of a letter from the NASDAQ Stock Market stating that the Company has regained compliance with the $1.00 minimum closing bid price requirement and that, accordingly, it has determined to continue the listing of EntreMed's common stock on the NASDAQ Capital Market.

20 Jul 2010

Aegera reports data from Phase 1 portion of combination AEG35156 Phase 1-2 study for primary liver cancer

Aegera Therapeutics Inc. released today encouraging survival data from the Phase 1 portion of its Phase 1-2 Study of the novel targeted therapeutic, AEG35156, given in combination with sorafenib in patients with advanced hepatocellular carcinoma (primary liver cancer).

20 Jul 2010

Researchers reveal findings on restricted lineage of iPS cells

Adult cells that have been reprogrammed into induced pluripotent stem cells (iPS cells) do not completely let go of their past, perhaps limiting their ability to function as a less controversial alternative to embryonic stem cells for basic research and cell replacement therapies, according to researchers at Children's Hospital Boston, John Hopkins University and their colleagues

20 Jul 2010

CytRx updates on progress in clinical development of bafetinib in three oncology indications

CytRx Corporation, a biopharmaceutical company specializing in oncology, announces progress with its clinical program to evaluate the preliminary efficacy and safety of its drug candidate bafetinib in three oncology indications. The Company has enrolled its first patient in a Phase 2 proof-of-concept trial in patients with high-risk B-cell chronic lymphocytic leukemia (B-CLL), is reporting rapid advancement toward the initiation of a Phase 2 proof-of-concept trial in advanced prostate cancer, and is on track to begin clinical evaluation later this year in glioblastoma multiforme, a common and aggressive type of primary brain tumor.

20 Jul 2010

Mayo Clinic's July issue offers tips on ophthalmology, Alzheimer's and CKD

Here are highlights from the July issue of Mayo Clinic Women's HealthSource. You may cite this publication as often as you wish. Mayo Clinic Women's HealthSource attribution is required.

20 Jul 2010

Researchers identify a mechanism that explains different phases of CML progression

Researchers at Duke University Medical Center have identified a mechanism that could explain how patients move into the worst phase of chronic myelogenous leukemia.

20 Jul 2010

FDA can promote personalized medicine by identying gaps in laboratory operations: ACLA

The Food and Drug Administration can promote progress toward personalized medicine by approaching the oversight of laboratory developed tests (LDTs) in a focused, flexible, and balanced way according to the American Clinical Laboratory Association (ACLA). ACLA, which represents the nation's leading clinical laboratories, says that the factors supporting this approach include the growing role that such tests play in clinical decision making, especially in the area of new advanced diagnostics that derive from the mapping of the human genome and help fulfill the promise of personalized medicine.

17 Jul 2010

All dementia isn't Alzheimer's disease: Mayo Clinic

Occasional misplaced keys or forgotten names don't mark the beginning of dementia. All dementia isn't Alzheimer's disease. Some dementia symptoms can be reversed. Those facts and many more are covered in Deciphering Dementia, a supplemental Special Report to the July issue of Mayo Clinic Women's HealthSource

16 Jul 2010

Arsenic nanoparticle to combat aggressive type of breast cancer prevalent in young women

You can teach an old drug new chemotherapy tricks. Northwestern University researchers took a drug therapy proven for blood cancers but ineffective against solid tumors, packaged it with nanotechnology and got it to combat an aggressive type of breast cancer prevalent in young women, particularly young African-American women.

16 Jul 2010

SWCRF/Emerald Foundation Global Collaborative Grant to fund critical cancer research

The leukemia stem cell-the root cause of all acute leukemias- represents a small population of cells in patients that are difficult to eliminate with standard treatments available today. Though current chemotherapy can produce temporary remission in leukemia survivors, they remain at risk of experiencing a recurrence and dying from the disease.

15 Jul 2010

EpiCept increases exercise price of June 2010 Warrants to $1.64 per share

EpiCept Corporation has amended the exercise price of its Series A Warrants and Series B Warrants sold in June 2010 from $1.57 per share to $1.64 per share. The exercise price was amended by Amendment No.1 dated as of July 8, 2010, to the Securities Purchase Agreement between EpiCept and each of the purchasers signatory thereto, which amended the Securities Purchase Agreement dated June 25, 2010 between EpiCept and each of the purchasers signatory thereto.

15 Jul 2010

Cord Blood America to close BioCells acquisition by August end

Cord Blood America, Inc., the umbilical cord blood stem cell preservation company focused on bringing the life-saving potential of stem cells, a biological insurance policy, to families nationwide and internationally, today announced that all preliminary due diligence is now complete for the acquisition of controlling interest in BioCells, Inc. BioCells is headquartered in Argentina, with affiliates under development in Peru, Colombia, Bolivia, Panama and Puerto Rico. The acquisition is expected to be closed no later than August 31, 2010.

14 Jul 2010

The Samuel Waxman Cancer Research Foundation announces research grants totaling $1.54 million

The Samuel Waxman Cancer Research Foundation (SWCRF) has awarded 13 collaborative research grants and 3 individual research grants, totaling $1.54 million. The 16 grants represent a portion of the science grant program at the Foundation, which will award more than $2 million this year to cancer research.

14 Jul 2010

ChemGenex agrees with FDA on potential regulatory path to progress OMAPRO for CML

ChemGenex Pharmaceuticals Limited announced today it has agreed with the U.S. Food and Drug Administration (FDA) on a potential regulatory path to progress OMAPRO™ (omacetaxine mepesuccinate) for the treatment of patients with Chronic Myeloid Leukemia (CML).

14 Jul 2010

Role of enzyme GSTP1-1 in progression of cancer, other diseases associated with increased cell proliferation

Telik, Inc. today announced the publication of a review in the journal, Cell Death and Differentiation: Glutathione transferases as mediators of signaling pathways involved in cell proliferation and cell death; http://www.nature.com/cdd/journal/vaop/ncurrent/full/cdd201080a.html. This review describes recent advances in the understanding of the important role that the enzyme GSTP1-1 plays in the progression of cancer and other diseases associated with increased cell proliferation.

13 Jul 2010

Wyse Technology announces partnership, continued success with LLS

Wyse Technology, the inventor and global leader in cloud client computing, today announced its partnership and continued success with The Leukemia and Lymphoma Society, the world's largest voluntary health organization dedicated to funding blood cancer research, education and patient services.

13 Jul 2010

EntreMed announces publication of preclinical data for ENMD-2076

EntreMed, Inc., today announced the publication of preclinical data for its Phase 2 oncology drug candidate, ENMD-2076 an Aurora A/angiogenic kinase inhibitor, which demonstrated significant activity against multiple myeloma cell lines and in MM models in vivo. Results of the study, conducted by EntreMed's collaborator, Sherif Farag, M.D., Ph.D., and colleagues at the Indiana University School of Medicine, were published in the on-line version of the British Journal of Haematology on June 15, 2010 and are scheduled to be published in print in the August 1, 2010 issue.

13 Jul 2010

LLS awards two new grants through prestigious Marshall A. Lichtman SCOR research initiative

The Leukemia & Lymphoma Society today announced it has awarded two new grants through its prestigious Marshall A. Lichtman Specialized Center of Research research initiative, bringing the program's total funding to $210.5 million since its inception in 2000.

13 Jul 2010

New study on impact of bortezomib on mantle cell lymphoma

A new study by researchers from the John Theurer Cancer Center at Hackensack University Medical Center sheds light on how bortezomib (VELCADE-), the first in a new class of cancer drugs known as proteasome inhibitors, works in mantle cell lymphoma. The study also provides preliminary evidence for which patients might benefit most from bortezomib.

13 Jul 2010

Stem cell transplantation from healthy donor helps cure aggressive form of CLL

The transplantation of stem cells from a healthy donor (allogeneic) offers the chance of cure for patients with an aggressive form of chronic lymphocytic leukemia (CLL), irrespective of genetic prognostic factors and the prior course of the disease. The German CLL Study Group proved this in a multicentric clinical phase II study led by Professor Dr. Peter Dreger, senior consultant and head of the division of stem cell transplantation at the Department of Internal Medicine V at Heidelberg University Hospital.

13 Jul 2010

Leukemia News and Research

Further Reading

EntreMed regains compliance with NASDAQ $1.00 minimum closing bid price requirement

Aegera reports data from Phase 1 portion of combination AEG35156 Phase 1-2 study for primary liver cancer

Researchers reveal findings on restricted lineage of iPS cells

CytRx updates on progress in clinical development of bafetinib in three oncology indications

Mayo Clinic's July issue offers tips on ophthalmology, Alzheimer's and CKD

Researchers identify a mechanism that explains different phases of CML progression

FDA can promote personalized medicine by identying gaps in laboratory operations: ACLA

All dementia isn't Alzheimer's disease: Mayo Clinic

Arsenic nanoparticle to combat aggressive type of breast cancer prevalent in young women

SWCRF/Emerald Foundation Global Collaborative Grant to fund critical cancer research

EpiCept increases exercise price of June 2010 Warrants to $1.64 per share

Cord Blood America to close BioCells acquisition by August end

The Samuel Waxman Cancer Research Foundation announces research grants totaling $1.54 million

ChemGenex agrees with FDA on potential regulatory path to progress OMAPRO for CML

Role of enzyme GSTP1-1 in progression of cancer, other diseases associated with increased cell proliferation

Wyse Technology announces partnership, continued success with LLS

EntreMed announces publication of preclinical data for ENMD-2076

LLS awards two new grants through prestigious Marshall A. Lichtman SCOR research initiative

New study on impact of bortezomib on mantle cell lymphoma

Stem cell transplantation from healthy donor helps cure aggressive form of CLL

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News